A relevant study on prostate cancer, which had integrated data from cell lines and clinical cohorts, revealed that COH29 inhibited oncogenic activity in vitro and could be a potential therapeutic option for this type of cancer, since RRM2 upregulation was related with poorer outcome [40]. This evidence concerns the gene RRM2 and prostate cancer.